Pliant Therapeutics, Inc. (PLRX) — 8-K Filings

8-K Filings (16)

• Pliant Therapeutics Appoints New Directors, Adjusts Executive Pay — Dec 16, 2025 Risk: medium
  Pliant Therapeutics, Inc. announced on December 10, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company e
• Pliant Therapeutics Appoints New CMO and CSO — Dec 8, 2025 Risk: medium
  Pliant Therapeutics, Inc. announced on December 2, 2025, the appointment of Dr. David J. Weitz as Chief Medical Officer and Dr. David M. Lee as Chief Scientific
• Pliant Therapeutics Announces Executive and Director Changes — Oct 24, 2025 Risk: medium
  Pliant Therapeutics, Inc. announced on October 20, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company re
• Pliant Therapeutics Terminates Material Definitive Agreement — Oct 20, 2025 Risk: medium
  Pliant Therapeutics, Inc. reported the termination of a material definitive agreement on October 14, 2025. The company, incorporated in Delaware with its princi
• Pliant Therapeutics Files 8-K for Corporate Updates — Jun 9, 2025 Risk: low
  Pliant Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting events as of June 5, 2025. The filing indicates amendments to its Articles of Incorporation or
• Pliant Therapeutics Files 8-K on Executive Changes & Exit Costs — May 1, 2025 Risk: medium
  Pliant Therapeutics, Inc. filed an 8-K on May 1, 2025, reporting on cost-associated exit or disposal activities and changes in directors or officers. The filing
• Pliant Therapeutics Files 8-K: Material Agreements & Bylaw Changes — Mar 13, 2025 Risk: medium
  Pliant Therapeutics, Inc. announced on March 12, 2025, the entry into a material definitive agreement. The company also reported modifications to the rights of
• Pliant Therapeutics Files 8-K — Feb 13, 2025 Risk: low
  Pliant Therapeutics, Inc. filed an 8-K on February 13, 2025, reporting other events and financial statements. The filing does not contain specific financial fig
• Pliant Therapeutics Files 8-K — Feb 10, 2025 Risk: low
  Pliant Therapeutics, Inc. filed an 8-K on February 10, 2025, reporting other events and financial statements/exhibits as of February 7, 2025. The filing does no
• Pliant Therapeutics Changes Fiscal Year End — Sep 27, 2024 Risk: low
  Pliant Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting a change in its fiscal year end from December 31 to September 30, effective September 24
• Pliant Therapeutics Files 8-K — Jul 15, 2024 Risk: low
  Pliant Therapeutics, Inc. filed an 8-K on July 15, 2024, to report other events and financial statements. The filing does not contain specific details about new
• Pliant Therapeutics Appoints New Chief Medical Officer — Jun 14, 2024 Risk: medium
  Pliant Therapeutics, Inc. announced on June 13, 2024, the appointment of Dr. David J. E. Mann as Chief Medical Officer. Dr. Mann previously served as Senior Vic
• Pliant Therapeutics Partners with Pfizer for IPF Drug — May 14, 2024 Risk: medium
  Pliant Therapeutics, Inc. announced on May 14, 2024, that it has entered into a strategic collaboration and license agreement with Pfizer Inc. This agreement fo
• Pliant Therapeutics Files Material Definitive Agreement — Mar 12, 2024 Risk: medium
  On March 11, 2024, Pliant Therapeutics, Inc. entered into a material definitive agreement, likely related to financing or a significant partnership, as indicate
• Pliant Therapeutics Files 8-K for Financial Results — Feb 27, 2024 Risk: low
  Pliant Therapeutics, Inc. filed an 8-K on February 27, 2024, to disclose its Results of Operations and Financial Condition, along with Financial Statements and
• PLIANT THERAPEUTICS FILES 8-K FOR UNSPECIFIED 'OTHER EVENT' — Feb 5, 2024
  Pliant Therapeutics, Inc. filed an 8-K on February 5, 2024, reporting an "Other Event" that occurred on February 4, 2024. This filing indicates a significant, b

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX